Healio Community Case in nAMD
Second-generation anti-vascular endothelial growth factor (VEGF) therapies with longer duration of action offer patients with neovascular age-related macular degeneration (nAMD) the potential for optimized visual and anatomical outcomes with extended intervals between doses. However, incorporating these newer therapies into individualized management protocols can be challenging. In this CE activity, Drs. Christina Weng and Nathan Steinle discuss individualized management options for a community-based nAMD patient case, offering insights into best practices for durable anti-VEGF therapeutic options through analysis of the latest clinical evidence and patient characteristics and preferences.
Cost: Free
View Offer chevron_rightDetails
Second-generation anti-vascular endothelial growth factor (VEGF) therapies with longer duration of action offer patients with neovascular age-related macular degeneration (nAMD) the potential for optimized visual and anatomical outcomes with extended intervals between doses. However, incorporating these newer therapies into individualized management protocols can be challenging. In this CE activity, Drs. Christina Weng and Nathan Steinle discuss individualized management options for a community-based nAMD patient case, offering insights into best practices for durable anti-VEGF therapeutic options through analysis of the latest clinical evidence and patient characteristics and preferences.
Topics Covered
nAMD
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Individualize the use of durable anti-VEGF options based on the latest evidence, patient characteristics, and preferences for patients with nAMD.
- Explore collaborative care approaches to address disparities in care surrounding the use of anti-VEGF treatments for patients with nAMD.
Target Audience
The intended audience for this activity is US-based ophthalmologists and retina specialists involved in the management of patients with or at risk for retinal diseases.